Profile data is unavailable for this security.
About the company
Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
- Revenue in EUR (TTM)487.56m
- Net income in EUR11.34m
- Incorporated1967
- Employees2.77k
- LocationBoiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
- Phone+33 478456100
- Fax+33 478456291
- Websitehttps://www.boiron.fr/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gufic BioSciences Ltd | 82.17m | 6.98m | 387.43m | 1.45k | 55.46 | 6.43 | 42.61 | 4.71 | 6.95 | 6.95 | 81.80 | 59.94 | 0.7249 | 1.80 | 2.54 | -- | 6.16 | 10.27 | 9.27 | 16.11 | 54.29 | 47.54 | 8.50 | 10.48 | 1.05 | 4.92 | 0.3587 | -- | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
Novoprotein Scientific Inc | 16.20m | -7.63m | 387.50m | 566.00 | -- | 1.54 | -- | 23.93 | -0.907 | -0.907 | 1.92 | 29.82 | 0.0596 | 0.6832 | 2.21 | 238,361.70 | -2.81 | 4.36 | -2.90 | 4.58 | 60.20 | 74.11 | -47.14 | 26.35 | 25.03 | -- | 0.0288 | 24.96 | -16.73 | 28.80 | -523.69 | -- | 166.98 | -- |
Boiron SA | 487.56m | 11.34m | 389.51m | 2.77k | 34.00 | 1.02 | 7.95 | 0.7989 | 0.6529 | 0.6529 | 28.08 | 21.78 | 0.8359 | 1.30 | 5.51 | 175,950.60 | 1.94 | 4.01 | 2.44 | 5.04 | 73.58 | 73.23 | 2.32 | 5.81 | 1.61 | -- | 0.0381 | 66.42 | -1.15 | -2.63 | -68.36 | -22.53 | -15.75 | 2.71 |
Knight Therapeutics Inc | 233.75m | 6.94m | 389.96m | 745.00 | 57.17 | 0.7764 | 9.84 | 1.67 | 0.1086 | 0.1086 | 3.68 | 8.00 | 0.3782 | 1.74 | 3.68 | 500,370.50 | 1.12 | 0.0976 | 1.30 | 0.1143 | 44.95 | 46.11 | 2.97 | 0.351 | 2.06 | -- | 0.0635 | 0.00 | 13.13 | 50.90 | 125.73 | -21.48 | 60.58 | -- |
ScinoPharm Taiwan Ltd | 94.06m | 7.19m | 392.79m | 1.01k | 54.79 | 1.25 | 18.08 | 4.18 | 0.3094 | 0.3094 | 4.05 | 13.51 | 0.2671 | 1.18 | 6.51 | -- | 2.04 | 2.55 | 2.18 | 2.71 | 36.61 | 40.54 | 7.64 | 9.59 | 5.09 | -- | 0.0612 | 104.55 | 6.91 | 3.32 | 18.22 | 9.39 | 22.27 | 5.33 |
Adcock Ingram Holdings Limited | 464.99m | 36.73m | 395.41m | 2.44k | 10.12 | 1.34 | -- | 0.8504 | 5.01 | 5.01 | 63.41 | 37.78 | 1.13 | 2.52 | 4.30 | 3,947,840.00 | 8.90 | 10.24 | 12.85 | 14.44 | 32.70 | 30.34 | 7.90 | 9.05 | 0.8498 | -- | 0.1488 | 41.41 | 5.60 | 6.38 | -9.39 | 3.37 | -9.93 | 6.58 |
Holder | Shares | % Held |
---|---|---|
Financi�re de l'�chiquier SAas of 31 Mar 2025 | 238.57k | 1.36% |
HMG Finance SAas of 30 Jun 2025 | 100.05k | 0.57% |
Dimensional Fund Advisors LPas of 04 Jul 2025 | 81.89k | 0.47% |
DNCA Finance SAas of 31 Mar 2023 | 74.85k | 0.43% |
HC Capital Advisors GmbHas of 31 Mar 2025 | 59.26k | 0.34% |
Amplegest SASas of 31 Dec 2024 | 46.82k | 0.27% |
Amiral Gestion SAas of 31 Dec 2024 | 42.16k | 0.24% |
Sycomore Asset Management SAas of 30 May 2025 | 38.68k | 0.22% |
Norges Bank Investment Managementas of 31 Dec 2024 | 28.80k | 0.16% |
Twenty First Capital SASas of 30 Jun 2023 | 21.50k | 0.12% |